{
    "clinical_study": {
        "@rank": "129299", 
        "arm_group": {
            "arm_group_label": "Inhaled milrinone 5 mg", 
            "arm_group_type": "Experimental", 
            "description": "Inhaled milrinone 5 mg(as for the injectable solution)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the concentration-effect relationship of inhaled\n      milrinone after prophylactic administration in cardiac surgical patients with preoperative\n      pulmonary hypertension undergoing cardiopulmonary bypass."
        }, 
        "brief_title": "Inhaled Milrinone in Cardiac Surgery", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": "Pulmonary Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Hypertension, Pulmonary"
            ]
        }, 
        "detailed_description": {
            "textblock": "Milrinone elimination will be verify with blood and urine samples analysis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients scheduled for elective cardiac surgery under CPB\n\n          -  High risk patients: NYHA class II-III\n\n          -  Preoperative diagnostic of pulmonary hypertension:\n\n               -  Systolic pulmonary artery pressure (sPAP) > 35 mm Hg; or\n\n               -  Mean pulmonary artery pressure (mPAP) > 25 mm Hg; or\n\n               -  mAP/mPAP < 3.0 (after induction of anesthesia).\n\n        Exclusion Criteria:\n\n          -  Open Heart Surgery\n\n          -  Contraindication to transesophageal echocardiography (TEE)\n\n          -  Hemodynamic instability before surgery\n\n          -  Emergency surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01725776", 
            "org_study_id": "ICM 06-888"
        }, 
        "intervention": {
            "arm_group_label": "Inhaled milrinone 5 mg", 
            "description": "Inhaled milrinone 5 mg (as for the injectable solution)", 
            "intervention_name": "Inhaled milrinone 5 mg", 
            "intervention_type": "Drug", 
            "other_name": "Primacor"
        }, 
        "intervention_browse": {
            "mesh_term": "Milrinone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pulmonary hypertension", 
            "Cardiac surgery", 
            "Cardiopulmonary Bypass (CPB)"
        ], 
        "lastchanged_date": "November 8, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Montreal", 
                    "country": "Canada", 
                    "state": "Quebec"
                }, 
                "name": "Montreal Heart Institute"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pharmacokinetic and Pharmacodynamic of Inhaled Milrinone in Cardiac Surgical Patients", 
        "overall_official": {
            "affiliation": "Montreal Heart Institute", 
            "last_name": "Andr\u00e9e Denault, MD PhD FRCPC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Study the elimination rate of milrinone administered by inhalation", 
            "safety_issue": "No", 
            "time_frame": "up to 24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01725776"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Montreal Heart Institute", 
            "investigator_full_name": "Andre Denault", 
            "investigator_title": "MD PhD FRCPC ABIM-CCM", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "hemodynamic values evaluated will be: central venous pressure, systolic and diastolic pulmonary pressure, wedge, cardiac output, cardiac frequency, systolic and diastolic pressure, SaO2, EtCO2. Patient will also have arterial and venous gaz.  Echographic values will be evaluated to see the cardiac fonction: left and right ventricular systolic and diastolic function and valvular function.", 
                "measure": "Demonstrate the presence or absence of hemodynamic and echographic effects observed after inhalation of milrinone", 
                "safety_issue": "Yes", 
                "time_frame": "15 min after the of study drug administration"
            }, 
            {
                "description": "Verification of the absence of deleterious effects on cardiac output and systemic arterial pressure.", 
                "measure": "Confirmation of the safety of inhaled milrinone", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours after cardiac surgery"
            }, 
            {
                "description": "Efficacy in the treatment of pulmonary hypertension is defined as a reduction of the mean pulmonary pressure of 10-20 %", 
                "measure": "Determination of the efficacy of inhaled milrinone in the treatment of pulmonary hypertension", 
                "safety_issue": "No", 
                "time_frame": "15 min after end of milrinone administration"
            }
        ], 
        "source": "Montreal Heart Institute", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Canadian Institutes of Health Research  (CIHR)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Fonds de la Recherche en Sant\u00e9 du Qu\u00e9bec", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hospital St. Justine", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Montreal Heart Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2006", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}